Anticoagulant Dosing Regimens, Switching Protocols, Complications, and Key Precautions
For VTE treatment in cancer patients, LMWH (specifically dalteparin 200 U/kg daily for 1 month, then 150 U/kg daily) is the preferred anticoagulant for both initial and long-term therapy, with DOACs (rivaroxaban or apixaban) as acceptable alternatives when LMWH is refused or impractical. 1, 2
Dosing Regimens by Clinical Setting
VTE Prophylaxis - Hospitalized Medical Patients
| Drug | Dose | Frequency | Key Adjustments |
|---|---|---|---|
| UFH | 5,000 U | Every 8 hours | None needed [3,1] |
| Enoxaparin | 40 mg SC | Once daily | CrCl <30: 1 mg/kg every 24h [3,1] |
| Dalteparin | 5,000 U SC | Once daily | Avoid if age >70y with renal insufficiency [4] |
| Fondaparinux | 2.5 mg SC | Once daily | Contraindicated if CrCl <30 mL/min [3,1] |
VTE Prophylaxis - Surgical Patients
| Drug | Preoperative Dose | Postoperative Dose | Duration |
|---|---|---|---|
| UFH | 5,000 U 2-4h before surgery | 5,000 U every 8h | Minimum 7-10 days [1] |
| Enoxaparin | 40 mg 2-4h or 10-12h before | 40 mg once daily | Minimum 7-10 days, consider 4 weeks for high-risk [1] |
| Dalteparin | 2,500 U 2-4h before OR 5,000 U 10-12h before | 5,000 U once daily | Minimum 7-10 days [1] |
| Fondaparinux | None | 2.5 mg starting 6-8h post-op | Minimum 7-10 days [1] |
VTE Prophylaxis - Cancer Outpatients
| Drug | Dose | Frequency | Evidence Level |
|---|---|---|---|
| Apixaban | 2.5 mg PO | Twice daily | Category 1 [1] |
| Rivaroxaban | 10 mg PO | Once daily | Category 1 [1] |
| Enoxaparin | 40 mg SC | Once daily | Alternative [1] |
| Dalteparin | 5,000 U SC | Once daily | Alternative [1] |
VTE Treatment - Initial Phase
| Drug | Loading/Initial Dose | Maintenance Dose | Renal Adjustments |
|---|---|---|---|
| UFH (IV) | 80 U/kg bolus | 18 U/kg/h, adjust to aPTT 1.5-2.0x control [1,5] | None needed |
| Enoxaparin | 1 mg/kg SC | Every 12h OR 1.5 mg/kg once daily | CrCl <30: avoid or monitor anti-Xa [3,1] |
| Dalteparin | 200 U/kg SC | Once daily OR 100 U/kg every 12h | CrCl <30: avoid or monitor anti-Xa [3,1] |
| Tinzaparin | 175 U/kg SC | Once daily | CrCl <30: avoid or monitor anti-Xa [3,1] |
| Fondaparinux | Weight-based: <50kg: 5mg; 50-100kg: 7.5mg; >100kg: 10mg | Once daily SC | Contraindicated if CrCl <30 [3,1] |
| Rivaroxaban | 15 mg PO | Twice daily x 21 days, then 20 mg once daily | Avoid if CrCl <30 [1,6] |
| Apixaban | 10 mg PO | Twice daily x 7 days, then 5 mg twice daily | Avoid if CrCl <25 [1] |
VTE Treatment - Long-Term Phase (After Initial 3 Months)
| Drug | Dose | Duration | Cancer-Specific Notes |
|---|---|---|---|
| Dalteparin | 200 U/kg daily x 1 month, then 150 U/kg daily | Indefinite while cancer active [1,2] | Preferred for cancer-associated VTE [2] |
| Enoxaparin | 1.5 mg/kg once daily OR 1 mg/kg every 12h | Indefinite while cancer active [1] | Alternative to dalteparin [2] |
| Rivaroxaban | 20 mg once daily (with food) | Minimum 6 months [1,6] | Acceptable alternative to LMWH [2] |
| Apixaban | 5 mg twice daily | Minimum 6 months [1] | Acceptable alternative to LMWH [2] |
| Edoxaban | 60 mg once daily (30 mg if weight <60kg or CrCl 30-50) | Minimum 6 months [1,6] | Requires ≥5 days parenteral anticoagulation first [6] |
| Warfarin | Adjust to INR 2-3 | Minimum 6 months [3,1] | Less preferred than LMWH in cancer [2] |
Extended-Phase VTE Treatment (Beyond 6 Months)
| Drug | Dose | Key Advantage |
|---|---|---|
| Apixaban (reduced) | 2.5 mg twice daily | Less bleeding than full-dose [7] |
| Rivaroxaban (reduced) | 10 mg once daily | Less bleeding than full-dose [7] |
| Aspirin | 81-100 mg daily | Only if anticoagulation stopped [7] |
STEMI Post-Fibrinolysis Anticoagulation
| Drug | Loading Dose | Maintenance | Duration |
|---|---|---|---|
| UFH | 60 U/kg IV (max 4,000 U) | 12 U/kg/h (max 1,000 U/h), aPTT 1.5-2.0x control | 48h or until revascularization [8] |
| Enoxaparin | Age <75y: 30 mg IV bolus; Age ≥75y: no bolus | Age <75y: 1 mg/kg SC q12h (max 100mg x2); Age ≥75y: 0.75 mg/kg q12h (max 75mg x2); CrCl <30: 1 mg/kg q24h | Up to 8 days or until revascularization [8] |
| Fondaparinux | 2.5 mg IV | 2.5 mg SC daily starting next day | Up to 8 days or until revascularization [8] |
Switching Between Anticoagulants
From Warfarin to DOAC
Stop warfarin and start DOAC when INR drops below specific threshold:
- To Dabigatran: Start when INR <2.0 9, 10
- To Rivaroxaban: Start when INR <3.0 9, 10
- To Apixaban: Start when INR <2.0 9, 10
- To Edoxaban: Start when INR ≤2.5 9, 10
From DOAC to Warfarin
Overlap required due to warfarin's delayed onset:
- From Dabigatran: Start warfarin based on CrCl: CrCl ≥50: start 3 days before stopping dabigatran; CrCl 30-50: start 2 days before; CrCl 15-30: start 1 day before 9, 11
- From Rivaroxaban: Start warfarin and continue rivaroxaban until INR ≥2.0 9, 11
- From Apixaban: Start warfarin and continue apixaban until INR ≥2.0 9, 11
- From Edoxaban: Reduce edoxaban to 30 mg and start warfarin simultaneously until INR ≥2.0 9, 11
From Parenteral Anticoagulant to DOAC
- To Rivaroxaban or Apixaban: Start at time of next scheduled parenteral dose (no overlap needed) 6, 9
- To Dabigatran or Edoxaban: Requires minimum 5 days parenteral anticoagulation first, then start at time of next scheduled dose 6, 9
From DOAC to Parenteral Anticoagulant
Start parenteral anticoagulant at time of next scheduled DOAC dose (no overlap or gap needed) 9, 11
Between DOACs
Direct switch at time of next scheduled dose - no bridging or overlap required 9, 11
From LMWH to Warfarin
Overlap for minimum 5 days and until INR ≥2.0 for 2 consecutive days 3, 5
Major Complications by Drug Class
Unfractionated Heparin (UFH)
- Heparin-Induced Thrombocytopenia (HIT): 1-5% risk, monitor platelets every 2-3 days up to day 14 4, 5
- Major bleeding: Higher than LMWH 3
- Osteoporosis: With prolonged use (>1 month)
- Hyperkalemia: Aldosterone suppression
Low Molecular Weight Heparin (LMWH)
- Accumulation in renal failure: Dose reduction or avoid if CrCl <30 mL/min 3, 1, 4
- HIT: Lower risk than UFH (0.2-0.6%) 4
- Spinal/epidural hematoma: Risk with neuraxial anesthesia - hold 10-12h before procedure 3
- Bleeding: Lower than UFH 3
Fondaparinux
- Contraindicated if CrCl <30 mL/min - no dose adjustment possible 3, 1, 4
- Caution if weight <50 kg or age >75 years 4
- No reversal agent available
- Lower HIT risk than heparins 4
Warfarin
- Narrow therapeutic window: Requires frequent INR monitoring 5
- Major bleeding: Especially intracranial hemorrhage
- Drug-food interactions: Vitamin K-containing foods, antibiotics, NSAIDs 5
- Skin necrosis: Rare, in protein C/S deficiency
- Teratogenic: Contraindicated in pregnancy 2
Dabigatran
- Dyspepsia: 10-15% incidence, most common side effect 2
- GI bleeding: May be higher than warfarin 2
- Coronary events: Possibly increased vs warfarin 2
- Renal elimination: Avoid if CrCl <30 mL/min 1, 6
Rivaroxaban
- GI bleeding: Higher than warfarin, especially at 20 mg dose 2
- Must take with food: 15 mg and 20 mg doses require food for absorption 1, 6
- Renal elimination: Avoid if CrCl <30 mL/min 1, 6
Apixaban
- Lowest bleeding risk among DOACs 2
- Less GI bleeding than dabigatran, rivaroxaban, edoxaban 2
- Renal elimination: Avoid if CrCl <25 mL/min 1
Edoxaban
- Paradoxically less effective if CrCl >95 mL/min - not recommended 6
- GI bleeding: May be higher than warfarin 2
- Requires parenteral lead-in: Minimum 5 days before starting 6
Critical Precautions by Drug
UFH
- Monitor aPTT every 6 hours until stable in therapeutic range (1.5-2.0x control) 8, 5
- Check platelets every 2-3 days for first 14 days to detect HIT 4, 5
- Protamine available for reversal (1 mg neutralizes 100 U heparin)
LMWH
- Check renal function before each dose adjustment - calculate CrCl, not just serum creatinine 3, 1
- Anti-Xa monitoring if CrCl 30-50 mL/min, weight >120 kg, or pregnancy (target 0.6-1.0 U/mL for twice daily, 1.0-2.0 U/mL for once daily) 3
- Avoid neuraxial anesthesia within 12 hours of prophylactic dose or 24 hours of therapeutic dose 3
- Partial reversal with protamine (1 mg neutralizes 1 mg enoxaparin, but only 60% effective)
Fondaparinux
- Absolute contraindication if CrCl <30 mL/min - no exceptions 3, 1, 4
- No reversal agent exists - consider this before urgent procedures
- Avoid if weight <50 kg unless benefit clearly outweighs risk 4
Warfarin
- Check INR at least weekly until stable, then monthly 5
- Avoid NSAIDs and COX-2 inhibitors - markedly increase bleeding risk 5
- Avoid certain antibiotics: Metronidazole, trimethoprim-sulfamethoxazole, fluoroquinolones 5
- Vitamin K for reversal: 5-10 mg IV slow push for major bleeding; oral 1-2.5 mg if INR 4.5-10 without bleeding 5
- Four-factor PCC preferred over FFP for urgent reversal (50 U/kg if INR 2-4,25 U/kg if INR <2) 5
Dabigatran
- Avoid if CrCl <30 mL/min 1, 6
- Dose reduce to 110 mg twice daily if age ≥80 years or high bleeding risk (not FDA-approved in US)
- Idarucizumab available for reversal (5 g IV)
- Avoid in coronary artery disease - consider alternative DOAC 2
- Take with water, not with food - food delays absorption
Rivaroxaban
- Must take 15 mg and 20 mg doses WITH FOOD - absorption reduced 30% without food 1, 6
- Avoid if CrCl <30 mL/min 1, 6
- Andexanet alfa available for reversal (low-dose 400 mg bolus + 480 mg infusion for <10h since dose; high-dose 800 mg bolus + 960 mg infusion for ≥10h or unknown)
- Check drug interactions: Strong CYP3A4 and P-gp inhibitors/inducers 1
Apixaban
- Dose reduce to 2.5 mg twice daily if ≥2 of: age ≥80 years, weight ≤60 kg, creatinine ≥1.5 mg/dL 1
- Avoid if CrCl <25 mL/min 1
- Andexanet alfa available for reversal (same dosing as rivaroxaban)
- Check drug interactions: Strong CYP3A4 and P-gp inhibitors/inducers 1
Edoxaban
- Do NOT use if CrCl >95 mL/min - paradoxically less effective 6
- Dose reduce to 30 mg daily if: weight ≤60 kg, CrCl 30-50 mL/min, or concomitant P-gp inhibitors 1, 6
- Requires ≥5 days parenteral anticoagulation before starting 6
- Do NOT overlap with warfarin when switching - unlike other DOACs 6
Special Populations
Cancer Patients
LMWH is strongly preferred over all other options for initial and long-term VTE treatment 2. DOACs are acceptable alternatives only when LMWH is refused or impractical (painful injections, cost, patient preference) 1, 2. The preference for LMWH is strongest in: newly diagnosed cancer, extensive VTE, metastatic disease, highly symptomatic patients, those vomiting, or receiving active chemotherapy 2.
Severe Renal Impairment (CrCl <30 mL/min)
Warfarin is the only safe oral option 2. All DOACs and LMWH are contraindicated or require extreme caution with anti-Xa monitoring 3, 1. UFH is safe as it has no renal elimination 5.
Liver Disease with Coagulopathy
LMWH preferred - DOACs contraindicated if INR elevated from liver disease; warfarin difficult to control and INR unreliable 2.
History of GI Bleeding
Apixaban or warfarin preferred - dabigatran, rivaroxaban, and edoxaban associated with more GI bleeding 2.
Pregnancy
LMWH only - all oral anticoagulants cross placenta and are contraindicated 2.